MEK Inhibitor, trametinib in children and adolescents subjects with cancer or plexiform neurofibromas and trametinib in combination with dabrafenib in children and adolescents with cancers harboring V600 mutations. Here, MAP2K7 is linked to plexiform neurofibroma.